KV Pharmaceutical's Launch of Gestiva(TM) Delayed
...n. 26 /PRNewswire-FirstCall/ -- KV Pharmaceutical
(NYSE: KVa/KVb) has been notified that the pending New Drug Application (NDA)
for Gestiva(TM) (alpha hydroxyprogesterone
caproate) will not be approved by
the U.S. Food and Drug Administration (FDA) until further conditions are met.
As previously disclosed, KV Pha...
KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE
..., the Company announced that it had entered into a
definitive purchase agreement that gives KV full U.S. and worldwide rights
to Gestiva(TM) (17-alpha hydroxyprogesterone
caproate) upon approval of the
pending Gestiva(TM) New Drug Application ("NDA"). The NDA for Gestiva(TM)
is currently before the FDA, pending approval...
Drug Therapy can Reduce Preterm Births and Decrease Lifetime Medical Costs
...ase Western Reserve University in Cleveland, OH found that treating expectant mothers// who have had previous spontaneous preterm births with 17 Alpha hydroxyprogesterone
caproate (17P) and reducing the incidence of another preterm birth would consequently reduce both short-term and lifetime medical costs in offspring b...